Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Breast02: Patritumab Deruxtecan + Trastuzumab Deruxtecan in HR+, HER2-low/ultralow Metastatic Breast Cancer
NCT07701941Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Jan 2031
- Countries
- 8
01
Overview
A Phase 2 trial of patritumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Sep 2026; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07701941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701941.